Chimeric anti-GPC3 sFv-CD3ε receptor-modified T cells with IL7 co-expression for the treatment of solid tumors

Chimeric antigen receptor (CAR) T cells targeting glypican-3 (GPC3) demonstrated early signs of therapeutic efficacy to hepatocellular carcinoma patients with a risk of cytokine release syndrome (CRS). Several adoptive cell therapies (ACTs) with T cells using the natural T cell receptor (TCR) signal...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yansha, Dong, Yiwei, Sun, Ruixin, Liu, Yifan, Wang, Yi, Luo, Hong, Shi, Bizhi, Jiang, Hua, Li, Zonghai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065615/
https://www.ncbi.nlm.nih.gov/pubmed/35572194
http://dx.doi.org/10.1016/j.omto.2022.04.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065615/
https://www.ncbi.nlm.nih.gov/pubmed/35572194
http://dx.doi.org/10.1016/j.omto.2022.04.003

Ejemplares similares